Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY – Get Free Report) was the target of a large growth in short interest during the month of July. As of July 15th, there was short interest totaling 48,491 shares, a growth of 279.3% from the June 30th total of 12,783 shares. Currently, 0.0% of the shares of the stock are short sold. Based on an average trading volume of 388,731 shares, the days-to-cover ratio is currently 0.1 days.
Analyst Ratings Changes
A number of analysts have recently issued reports on SGIOY shares. Zacks Research upgraded Shionogi & Co., Ltd. Unsponsored ADR from a “strong sell” rating to a “hold” rating in a report on Monday, May 25th. The Goldman Sachs Group raised shares of Shionogi & Co., Ltd. Unsponsored ADR from a “hold” rating to a “strong-buy” rating in a research report on Monday, June 15th. Finally, Jefferies Financial Group upgraded shares of Shionogi & Co., Ltd. Unsponsored ADR from a “hold” rating to a “strong-buy” rating in a report on Tuesday, July 14th. Two equities research analysts have rated the stock with a Strong Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Buy”.
Read Our Latest Research Report on SGIOY
Shionogi & Co., Ltd. Unsponsored ADR Stock Up 0.6%
Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY – Get Free Report) last issued its earnings results on Tuesday, May 12th. The company reported $0.18 EPS for the quarter, beating analysts’ consensus estimates of $0.15 by $0.03. Shionogi & Co., Ltd. Unsponsored ADR had a return on equity of 13.56% and a net margin of 41.08%.The firm had revenue of $881.71 million for the quarter, compared to the consensus estimate of $895.52 million. As a group, research analysts predict that Shionogi & Co., Ltd. Unsponsored ADR will post 0.79 earnings per share for the current fiscal year.
Shionogi & Co., Ltd. Unsponsored ADR Company Profile
Shionogi & Co, Ltd. is a Japan-based pharmaceutical company that conducts research, development, manufacturing and marketing of prescription drugs and vaccines. Established in the late 19th century, the company has expanded its focus beyond domestic markets to become a global player in pharmaceuticals, with particular expertise in anti-infectives, pain management, cardiovascular and central nervous system disorders.
The company’s product portfolio spans both established and innovative therapies.
Featured Stories
- Five stocks we like better than Shionogi & Co., Ltd. Unsponsored ADR
- Broadcom May Be the Biggest Winner From Alphabet’s Earnings
- Volatility Is Back and These 3 Market Tollbooths Are Best Positioned to Profit
- 2 Stocks Built to Thrive If Inflation Refuses to Fade
- Telecom Earnings Reveal a Sector That Finally Looks Healthier
Receive News & Ratings for Shionogi & Co. Ltd. Unsponsored ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shionogi & Co. Ltd. Unsponsored ADR and related companies with MarketBeat.com's FREE daily email newsletter.
